Abstract
The role of eicosanoids as mediators of inflammation in the course of renal allograft rejection is reviewed. Elucidation of their particular roles has come from the use of specific inhibitors, and one looks forward to their application in human transplant management. As illustrated by the experience with the use of fish oils, additional benefit over that of standard immunosuppression is anticipated but quantitating that benefit in individuals may not be easy.

This publication has 0 references indexed in Scilit: